People on the Move: February 2022

By Jenni Spinner

03-Feb-2022 - Last updated on 09-Feb-2022 at 09:06 GMT

(z_wei/iStock via Getty Images Plus)

This month’s announcements include new hires, promotions, acquisitions, and other events from Saama, Javara, Firma, GlaxoSmithKline, and other companies.

People on the Move: February 2022

Javara: Tim Neathery, chief human resources officer

Thread: acquisition of inVibe

GlaxoSmithKline: Tony Wood, chief scientific officer

Worldwide Clinical Trials: partnership with Science 37

Firma Clinical Research: Jennifer Mintz, chief commercial officer

Centricity Research: new name

Saama Technologies: Scott Rogers, chief financial officer

Publicis Health: acquisition of BBK Worldwide

Metrics Contract Services: Kim Black-Washington, senior business development executive

Recipharm: sale of solid-dose manufacturing site in France

Related tags Mergers and acquisitions

Related news

Show more

Related products

show more

Generic method approach for determination of residual solvents in active pharmaceutical ingredients by gas chromatography

Content provided by Almac Group | 29-Nov-2023 | White Paper

Solvents are defined as organic chemicals that are used to dissolve components. They are used during the manufacture of drug substances and can also potentially...

Almac Group releases 2023 Corporate Social Responsibility Report

Content provided by Almac Group | 14-Nov-2023 | Application Note

Almac Group today announces the release of the company’s 2023 Corporate Social Responsibility report, which highlights Almac’s progress and commitments...

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars

On-demand webinars

Headlines

Promotional Features